| Literature DB >> 27492012 |
B K Somani1, G Giusti2, Y Sun3, P J Osther4, M Frank5, M De Sio6, B Turna7, J de la Rosette8.
Abstract
INTRODUCTION: Ureterorenoscopy (URS) is a popular and growing option for management of ureteric and renal stones. The CROES URS Global Study was set up to assess the outcomes of URS in a large worldwide cohort of patients involving multiple centres. In this paper, we analysed the database for intra-operative and post-operative complications associated with ureterorenoscopy.Entities:
Keywords: Clavien–Dindo; Complications; Ureterorenoscopy; Urolithiasis
Mesh:
Year: 2016 PMID: 27492012 PMCID: PMC5364249 DOI: 10.1007/s00345-016-1909-0
Source DB: PubMed Journal: World J Urol ISSN: 0724-4983 Impact factor: 4.226
Descriptive information on the CROES URS Global study
| Patients with complications | Patients without complications | |
|---|---|---|
|
| ||
| Age | 51.7 (16.3) | 48.4 (15.8) |
| Gender | ||
| Male | 556 (63.7) | 7145 (65.0) |
| Female | 317 (36.3) | 3842 (35.0) |
| BMI | 26.7 (5.2) | 27.0 (5.4) |
| Comorbidity | ||
| CVD (including DM) | 357 (40.9) | 3233 (29.4) |
| Prednisone | 14 (1.6) | 92 (0.9) |
| Crohn’s disease | 8 (0.9) | 51 (0.5) |
| ASA | ||
| I | 324 (39.3) | 5672 (55.4) |
| II | 356 (43.2) | 3635 (35.5) |
| III | 137 (16.6) | 884 (8.6) |
| IV | 7 (0.9) | 56 (0.6) |
| Stone location | ||
| Ureteral stones | 209 (62.9) | 8068 (73.4) |
| Renal stones | 550 (23.9) | 1597 (14.5) |
| Combined procedure | 83 (9.5) | 975 (8.9) |
| Previous stone treatment | 456 (52.2) | 4482 (40.8) |
| Congenital abnormalities | ||
| Horse shoe | 5 (0.6) | 40 (0.4) |
| Malrotation | 1 (0.1) | 16 (0.2) |
| Ectopic | 5 (0.6) | 23 (0.2) |
| Solitary kidney | 38 (4.4) | 274 (2.5) |
| Pre-operative stent placement | 194 (22.3) | 1985 (18.1) |
|
| ||
| Operation time (min) | 50 (33–75) | 40 (25–60) |
| URS type | ||
| Semi rigid | 562 (64.5) | 8204 (74.9) |
| Flexible | 174 (20.0) | 1607 (14.7) |
| Both | 135 (15.5) | 1138 (10.4) |
| Antibiotics | 775 (89.3) | 9019 (83.0) |
| Access* | ||
| Balloon | 72 (8.2) | 1505 (13.7) |
| Access Sheath | 252 (28.8) | 2011 (18.3) |
| Guidewire | 722 (82.6) | 8475 (77.2) |
| Other | 20 (2.3) | 264 (2.4) |
| Fragmentation device | ||
| US | 25 (2.9) | 121 (1.1) |
| Laser | 413 (47.5) | 5500 (50.2) |
| Pneumatic | 180 (20.7) | 3456 (31.5) |
| EHL | 5 (0.6) | 29 (0.3) |
| Other | 4 (0.5) | 210 (1.9) |
| None | 242 (27.9) | 1679 (15.3) |
|
| ||
| Retreatment including readmission | 407 (46.6) | 1490 (13.6) |
| SFR (treated area) | 514 (59.8) | 9682 (89.9) |
| LOHS (days) | 2 (1–4) | 1 (1–2) |
| Post-operative stent placement | 769 (88.8) | 8888 (81.0) |
|
| ||
| Economy | ||
| Developed region: G7 | 281 (32.2) | 2828 (25.7) |
| Developed region: non-G7 | 286 (32.7) | 2776(25.3) |
| Emerging region: BRIC | 107 (12.2) | 2102 (19.1) |
| Emerging region: MICT | 100 (11.4) | 1233 (11.2) |
| Emerging region: G20 | 92 (10.5) | 1974 (18.0) |
| Developing region | 8 (0.9) | 81 (0.7) |
| Continent | ||
| Africa | 40 (4.6) | 397 (3.6) |
| Asia | 231 (26.4) | 4478 (40.7) |
| Europe | 495 (56.6) | 4721 (42.9) |
| North America | 65 (7.4) | 776 (7.1) |
| Oceania | 6 (0.7) | 53 (0.5) |
| South America | 37 (4.2) | 569 (5.2) |
| Case volume | 4.8 (4.2–5.3) | 5.0 (4.4–5.9) |
Data are n (%) of patients for whom data were available. Percentages exclude missing values from denominators
* More than one option allowed
Descriptive information on intra- and post-operative complications
| Number | % | |
|---|---|---|
|
| ||
| Bleeding | 167 | 1.41 |
| Perforation | 124 | 1.05 |
| Failed access | 198 | 1.67 |
| Conversions | 19 | 0.16 |
| Other | 100 | 0.84 |
| Mucosal injury | 15 | 0.13 |
| Tumour (incidental) | 7 | 0.06 |
| Migration | 15 | 0.13 |
| Impacted stone | 4 | 0.03 |
| Encrusted stent | 7 | 0.06 |
| Infection | 8 | 0.07 |
| Complication NOT by URS | 8 | 0.07 |
| Undefined | 36 | 0.30 |
|
| ||
| Bleeding | 54 | 0.45 |
| Fever | 204 | 1.72 |
| UTI | 113 | 0.95 |
| Pulmonary embolism | 2 | 0.02 |
| CVA | 1 | 0.01 |
| Sepsis | 36 | 0.30 |
| Acute abdomen | 5 | 0.04 |
| AMI | 1 | 0.01 |
| Pain | 39 | 0.33 |
| Urinary retention | 13 | 0.11 |
| Stent misplacement | 12 | 0.10 |
| Nausea and vomiting | 3 | 0.03 |
| Respiratory | 5 | 0.04 |
| Allergy | 5 | 0.04 |
| Other | 17 | 0.15 |
Fig. 1Clavien score by type of post-operative complication